| SARS-CoV-2-related atypical thyroiditis I Muller, D Cannavaro, D Dazzi, D Covelli, G Mantovani, A Muscatello, ... The lancet Diabetes & endocrinology 8 (9), 739-741, 2020 | 334 | 2020 |
| Anti-diabetic drugs and weight loss in patients with type 2 diabetes E Lazzaroni, MB Nasr, C Loretelli, I Pastore, L Plebani, ME Lunati, ... Pharmacological Research 171, 105782, 2021 | 99 | 2021 |
| The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists G Bendotti, L Montefusco, ME Lunati, V Usuelli, I Pastore, E Lazzaroni, ... Pharmacological Research 182, 106320, 2022 | 88 | 2022 |
| Cholesterol serum levels and use of statins in Graves' orbitopathy: a new starting point for the therapy G Lanzolla, G Vannucchi, I Ionni, I Campi, F Sileo, E Lazzaroni, M Marinò Frontiers in Endocrinology 10, 933, 2020 | 42 | 2020 |
| Efficacy profile and safety of very low-dose rituximab in patients with Graves' orbitopathy G Vannucchi, I Campi, D Covelli, N Currò, E Lazzaroni, A Palomba, ... Thyroid 31 (5), 821-828, 2021 | 32 | 2021 |
| Prevention of orbitopathy by oral or intravenous steroid prophylaxis in short duration Graves' disease patients undergoing radioiodine ablation: a prospective randomized … G Vannucchi, D Covelli, I Campi, N Currò, D Dazzi, M Rodari, G Pepe, ... Thyroid 29 (12), 1828-1833, 2019 | 28 | 2019 |
| Dapagliflozin acutely improves kidney function in type 2 diabetes mellitus. The PRECARE study E Lazzaroni, ME Lunati, L Montefusco, I Pastore, E Chebat, V Cimino, ... Pharmacological Research 183, 106374, 2022 | 14 | 2022 |
| Therapy with different dose regimens of rituximab in patients with active moderate-to-severe Graves’ orbitopathy I Campi, G Vannucchi, I Muller, E Lazzaroni, N Currò, M Dainese, ... Frontiers in Endocrinology 12, 790246, 2022 | 13 | 2022 |
| SARS-CoV-2-related atypical thyroiditis. Lancet Diabetes Endocrinol 8 (9): 739–741 I Muller, D Cannavaro, D Dazzi, D Covelli, G Mantovani, A Muscatello, ... | 12 | 2020 |
| The anti-inflammatory and immunological properties of SGLT-2 inhibitors G Bendotti, L Montefusco, I Pastore, E Lazzaroni, ME Lunati, P Fiorina Journal of Endocrinological Investigation 46 (12), 2445-2452, 2023 | 8 | 2023 |
| Quantification of global ocular motility impairment in Graves' orbitopathy by measuring eye muscle ductions I Campi, N Currò, G Vannucchi, D Covelli, S Simonetta, L Fugazzola, ... Thyroid 31 (2), 280-287, 2021 | 7 | 2021 |
| SARS-CoV-2-related atypical thyroiditis. Lancet Diabetes Endocrinol. 8, 739–741 (2020) I Muller, D Cannavaro, D Dazzi, D Covelli, G Mantovani, A Muscatello, ... | 6 | 2003 |
| Efficacy of the anti-BAFF monoclonal antibody belimumab vs methylprednisolone in active moderate-severe graves’ orbitopathy: preliminary analysis of a randomized controlled trial F Vittoria, N Currò, I Campi, E Lazzaroni, D Covelli, G Vannucchi, D Dazzi, ... Endocrine Abstracts 73, 2021 | 2 | 2021 |
| Type 2 diabetes mellitus pharmacological remission with dapagliflozin plus oral semaglutide ME Lunati, V Cimino, D Bernasconi, A Gandolfi, PS Morpurgo, C Tinari, ... Pharmacological Research 199, 107040, 2024 | 1 | 2024 |
| Efficacy Profile and Safety of Very Low-Dose Rituximab in Patients with Graves' Orbitopathy by Vannucchi (vol 31, pg 821, 2021) G Vannucchi, I Campi, D Covelli, N Curro, E Lazzaroni, A Palomba, ... THYROID 32 (5), 605-605, 2022 | | 2022 |
| Retrospective analysis of the efficacy of three different dose regimens of rituximab in patients with active moderate-severe graves E Lazzaroni, D Covelli, I Campi, G Vannucchi, N Curro, G Pirola, ... Endocrine Abstracts 63, 2019 | | 2019 |
